WEBULL
News
LNTH
66.71
+0.05%
0.03
Lantheus Exit: $28 Million Sale Comes as Earnings Fall 77% Year Over Year
NASDAQ · 4d ago
Solventum is the top performing healthcare supplies stock YTD
Seeking Alpha · 5d ago
Weekly Report: what happened at LNTH last week (1215-1219)?
Weekly Report · 5d ago
Lifeward chairman Joseph Turk to depart, Lantheus CFO Bob Marshall to succeed
TipRanks · 12/19 21:15
Lantheus Holdings Is Maintained at Buy by Truist Securities
Dow Jones · 12/18 14:43
Lantheus Holdings Price Target Raised to $82.00/Share From $80.00 by Truist Securities
Dow Jones · 12/18 14:43
Truist Securities Maintains Buy on Lantheus Holdings, Raises Price Target to $82
Benzinga · 12/18 14:33
Lantheus price target raised to $82 from $80 at Truist
TipRanks · 12/18 14:16
U.S. RESEARCH ROUNDUP-Autozone, Coursera, Lennar
Reuters · 12/18 06:42
Lantheus Holdings Price Target Raised to $72.00/Share From $60.00 by Mizuho
Dow Jones · 12/17 13:16
Lantheus Holdings Is Maintained at Outperform by Mizuho
Dow Jones · 12/17 13:16
Mizuho Maintains Outperform on Lantheus Holdings, Raises Price Target to $72
Benzinga · 12/17 13:06
Weekly Report: what happened at LNTH last week (1208-1212)?
Weekly Report · 12/15 09:34
Lantheus Holdings Raised to Buy From Hold by Truist Securities
Dow Jones · 12/12 14:54
Lantheus Holdings Price Target Raised to $80.00/Share From $61.00 by Truist Securities
Dow Jones · 12/12 14:54
Truist Securities Upgrades Lantheus Holdings to Buy, Raises Price Target to $80
Benzinga · 12/12 14:44
Why Lantheus (LNTH) Stock Is Up Today
Barchart · 12/12 12:08
LANTHEUS HOLDINGS INC <LNTH.O>: TRUIST SECURITIES RAISES TO BUY FROM HOLD; RAISES TARGET PRICE TO $80 FROM $61
Reuters · 12/12 05:02
Lantheus upgraded to Buy at Truist on profit re-acceleration prospects
TipRanks · 12/11 21:35
Lantheus upgraded to Buy from Hold at Truist
TipRanks · 12/11 21:30
More
Webull provides a variety of real-time LNTH stock news. You can receive the latest news about Lantheus Holding through multiple platforms. This information may help you make smarter investment decisions.
About LNTH
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company engaged in delivering science to enable clinicians to find, fight and follow diseases to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Radiopharmaceutical Oncology diagnostics and therapeutics help healthcare professionals (HCPs) find, fight and follow cancer, with a focus on prostate cancer. Precision Diagnostic products assist HCPs to find and follow diseases, with a focus on cardiology. Strategic Partnerships focus on enabling precision medicine through the use of biomarker solutions, digital solutions, and radiotherapeutic platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, Neuraceq, and others. Its clinical candidates include LNTH-2404, NAV-4694, and PNT2002, among others. The Neuraceq (florbetaben F18 injection) is an F-18 PET imaging agent for Alzheimer’s disease.